Relevant Articles About Research and Clinical Trials in Lymphoma
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The INDYGO trial aimed to provide patients with updated exploratory analyses on OS, PFS, and HRQOL. The study concluded that intraoperative PDT alongside surgical excision and standard adjuvant therapy improved outcomes. Despite optimal multimodal...
KEY TAKEAWAYS The study aimed to investigate the efficacy and safety of NAIT in patients with GEJC. Researchers noticed the efficacy of NAIT in resectable GEJC alongside an acceptable toxicity profile; further investigation is ongoing. In recent years, neoadjuvant...
KEY TAKEAWAYS The study aimed to compare populations with differing childbirth ages to assess breast cancer and childbearing age overlap. The study emphasized increased awareness for women to make informed choices about delayed childbearing and cancer prevention....
The phase 2 trial aimed to investigate the efficacy of ruxolitinib in T-cell LGL leukemia pts by targeting JAK/STAT pathway. Researchers noticed durable …
The ZUMA-7 phase 3 trial aimed to investigate the safety and efficacy of axicabtagene ciloleucel as second-line therapy relapsed/refractory large B-cell lymphoma pts. …
The phase I/II trials aimed to evaluate the pirtobrutinib’s enduring efficacy and safety in heavily pretreated CLL/SLL patients relapsed post-cBTKi. The various endpoints …
Background Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computational framework, REAL-neo, for identification, …
Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to …
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological …
Background Cancer-intrinsic type I interferon (IFN-I) production triggered by radiotherapy (RT) is mainly dependent on cytosolic double-stranded DNA (dsDNA)-mediated cGAS/STING signaling and increases cancer immunogenicity and enhances the antitumor immune response to increase therapeutic efficacy. However, …